Researchers report in the July 2000 issue of the "Journal of
Immunology" that tetrahydrocannabinol (THC), the major
psychoactive component of marijuana, can promote tumor
growth by impairing the body's anti-tumor immunity system.
While previous research has shown that THC can lower
resistance to both bacterial and viral infections, this is
the first time that its possible tumor-promoting activity
has been reported.
A team of researchers at UCLA's Jonsson Comprehensive Cancer
Center found in experiments in mice that THC limits immune
response by increasing the availability of two forms (IL-10
and TGF-ß) of cytokine, a potent, tumor-specific, immunity
suppresser.
The authors also suggest that smoking marijuana may be more
of a cancer risk than smoking tobacco. The tar portion of
marijuana smoke, compared to that of tobacco, contains
higher concentrations of carcinogenic hydrocarbons,
including benzapyrene, a key factor in promoting human lung
cancer. And marijuana smoke deposits four times as much tar
in the respiratory tract as does a comparable amount of
tobacco, thus increasing exposure to carcinogens.
Dr. Steven M. Dubinett, head of the research team that
conducted the study, says, "What we already know about
marijuana smoke, coupled with our new finding that THC may
encourage tumor growth, suggests that regular use of
marijuana may increase the risk of respiratory tract cancer
and further studies will be needed to evaluate this
possibility."
The UCLA researchers examined the effects of THC on the
immune response to lung cancer in mice. Over a two-week
period, the animals were injected four times per week with
either THC or a saline solution. Fourteen days after the
injections were started, murine Lewis lung cancer and line 1
alveolar cell cancer cells were implanted in the mice. The
mice continued to receive THC or saline injections after the
tumor cells were implanted, and tumor growth was assessed
three times each week. To test the hypothesis that THC
impairs tumor-specific immune system response, a group of
mice with compromised immune systems was also studied.
The researchers found that in the mice with normal immune
systems there was significant enhancement of tumor growth,
but THC had no effect on tumor growth in the immunodeficient
mice. The study also showed that when lymphocytes from the
THC-treated mice were injected into untreated mice, the
immune deficit was transferred and tumor growth was
accelerated in the normal controls.
Additionally, the UCLA research team demonstrated that when
anti-IL-10 and anti-TGF-ß were administered, there was no
acceleration of tumor growth in THC-treated mice. These
results suggest that enhanced tumor growth is prompted by
THC's ability to stimulate production of IL-10 and TGF-ß,
which inhibits anti-tumor immune response.
The National Institute on Drug Abuse is a component of the
National Institutes of Health, U.S. Department of Health and
Human Services. NIDA supports more than 85 percent of the
world's research on the health aspects of drug abuse and
addiction. The Institute carries out a large variety of
programs to ensure the rapid dissemination of research
information and its implementation in policy and practice.
Fact sheets on the health effects of drugs of abuse and
other topics can be ordered free of charge in English and
Spanish by calling NIDA Infofax at 1-888-NIH-NIDA (644-6432)
or 1-888-TTY-NIDA (889-6432) for the deaf. These fact sheets
and further information on NIDA research and other
activities can be found on the NIDA home page at
www.drugabuse.gov.